Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

HIV variability and perspectives for a vaccine

P Verani1, S Buttò, B Taddeo

  • 1Laboratory of Virology, Istituto Superiore di Sanità, Rome, Italy.

Vaccine
|January 1, 1993
PubMed
Summary

Developing an effective AIDS vaccine involves inducing neutralizing antibodies against the HIV-1 principal neutralizing determinant (PND). Strategies include using peptide cocktails and exploring intracellular immunity for HIV resistance.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nerve-sparing total prostatectomy with or without adjuvant chemotherapy is associated with a low rate of surgical complications, long-term continence and improved survival in 22 dogs with T1 to T3 prostatic tumours.

The Journal of small animal practice·2026
Same author

Peripheral T- and natural killer-cell lymphomas: ESMO-EHA Clinical Practice Guideline for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Oligometastatic sarcoma treated with Curative intent Ablative Radiotherapy (OSCAR): A multicenter study on behalf of AIRO (Italian association of Radiotherapy and clinical Oncology).

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2024
Same author

Stereotactic Body Radiotherapy for Spine Oligometastases: A Multicentre Retrospective Study From the Italian Association of Radiotherapy and Clinical Oncology (AIRO).

Clinical oncology (Royal College of Radiologists (Great Britain))·2023
Same author

Epidemiological and molecular characterization of HBV and HCV infections in HIV-1-infected inmate population in Italy: a 2017-2019 multicenter cross-sectional study.

Scientific reports·2023
Same author

Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2018

Area of Science:

  • Immunology
  • Virology
  • Vaccine Development

Background:

  • Developing an effective vaccine against Acquired Immunodeficiency Syndrome (AIDS) remains a critical global health challenge.
  • Neutralizing antibodies targeting the Human Immunodeficiency Virus type 1 (HIV-1) envelope are essential for vaccine-induced protection.
  • The Principal Neutralizing Determinant (PND) is a key target for antibody induction, but its variability poses a significant hurdle.

Purpose of the Study:

  • To review strategies for inducing neutralizing antibodies against HIV-1 for vaccine development.
  • To explore methods for overcoming PND variability in HIV-1.
  • To investigate alternative approaches like intracellular immunity for HIV resistance.

Main Methods:

  • Analysis of PND structure and variability in HIV-1 isolates.

Related Experiment Videos

  • Development and testing of synthetic peptides representing PND sequences.
  • Construction of hybrid immunogens incorporating diverse PND sequences.
  • Characterization of a cellular clone (F12) exhibiting resistance to HIV infection.

    • Main Results:

    • Synthetic peptides representing PND can induce neutralizing antibodies.
    • Peptide cocktails and hybrid immunogens show promise in overcoming PND variability.
    • The F12 cellular clone, despite harboring HIV-1, resists viral particle release and superinfection.
    • The F12 clone demonstrates potential for inducing homologous viral interference.

    Conclusions:

    • Targeting the HIV-1 PND with diverse peptide immunogens is a viable strategy for vaccine development.
    • Intracellular immunity, exemplified by the F12 clone, offers a novel approach to confer HIV resistance.
    • Further research into transferring the F12/HIV genome could lead to robust cellular resistance against HIV infection.